The company relies on sole-source third-party contract manufacturers for clinical trial materials, including Varseta-M and CX-801. It does not have long-term contracts or alternative suppliers readily available, which presents risks of supply interruptions, quality issues, and delays. Replacing manufacturers is challenging due to limited qualified options, technology transfer complexities, and potential regulatory delays. Scaling up manufacturing for later-stage trials and commercial production may be difficult and costly. Changes in drug formulation and manufacturing processes require FDA bridging studies to ensure comparability, with no guarantee of timely or successful completion. The company holds an exclusive license agreement with the University of California, Santa Barbara (UCSB) for certain patent rights related to pro-protein biologics and conditionally activatable antibodies, which involves royalty and milestone payment obligations to UCSB.
Cytomx Therapeutics Inc's Comment on Supply Chain
The company relies on sole-source third-party contract manufacturers for clinical trial materials, including Varseta-M and CX-801. It does not have long-term contracts or alternative suppliers readily available, which presents risks of supply interruptions, quality issues, and delays. Replacing manufacturers is challenging due to limited qualified options, technology transfer complexities, and potential regulatory delays. Scaling up manufacturing for later-stage trials and commercial production may be difficult and costly. Changes in drug formulation and manufacturing processes require FDA bridging studies to ensure comparability, with no guarantee of timely or successful completion. The company holds an exclusive license agreement with the University of California, Santa Barbara (UCSB) for certain patent rights related to pro-protein biologics and conditionally activatable antibodies, which involves royalty and milestone payment obligations to UCSB.
Sources:
Cytomx Therapeutics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Cytomx Therapeutics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
